TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Detection and diagnosis of abnormal growths and early cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction in Daily Genital Pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in supraspinatus tendon elasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Participants with death or severe disability
Endpoint domain: Mortality/survival
Primary endpoint: seizure freedom rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Yield of exome results
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Detection of Hyperemia or Oligemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annual change in systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of patients offered genetic testing
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change from baseline in Visual Analogic Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Effectiveness of colon-rectal cancer screening reminder program
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Degree of brow lift achieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Menstrual irregularity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Incidence of early VAP
Endpoint domain: Adverse events/effects
Primary endpoint: Glucose Metabolic Rate (GMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decrease in symptoms of constipation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Sexual Encounter Profile question 2 (SEP 2)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of Adverse Events (AE) and Dose Limiting Toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Any Serious Adverse Event (SAE) and Any Non Serious Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Systolic Blood Pressure and Diastolic Blood Pressure of Participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Heart Rate of Participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Reduction in Plasma Intact Parathyroid Hormone (iPTH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Composite of death, large recurrent myocardial infarction (MI), urgent target vessel revascularization (TVR) or major bleeding
Endpoint domain: Mortality/survival
Primary endpoint: Ridge volume loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eating Disorder Examination Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Detection of Cav1 sequence coding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Walking distance during the six-minute walking test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate to Gemcitabine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving a 50% reduction of depressive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients maintaining a response defined by MADRS total score of <14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Distribution of C11 PiB in the Brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Distribution of F18 Flutemetamol in the Brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hematopoietic Recovery and Engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Single procedure success of cryoballoon ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: soluble intercellular adhesion molecule-1 (sICAM-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: soluble vascular adhesion molecule-1 (sVCAM-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area of brain activation during motor task performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Average Morning Fasting Free Testosterone Blood Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Electrophysiological outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Working memory outcomes
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Reduction of Dysmenorrhea (DYS) at Month 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Reduction of Non-menstrual Pelvic Pain (NMPP) at Month 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Health Care utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Patients' perceptions regarding safety
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Peak Plasma Concentration (CMAX) of montelukast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of montelukast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of surgical resection
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of surgical resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Paracetamol concentration time curve at STEMI onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Paracetamol concentration time curve 72 hours after STEMI onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Paracetamol concentration time curve for stable patient group
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative abscess
Endpoint domain: Adverse events/effects
Primary endpoint: Risk of severe respiratory deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in peripheral and central blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent of Eligible Dyads Who Would Consent to Enroll
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percent of Parents Who Would Recommend This Program to Other Parents of Preterm Infants
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent of Parents Who Complete All Protocol Components
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Investigator Global Assessment (IGA) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eczema Area Severity Index (EASI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Pruritus Numeric Rating Scale (NRS)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Whole body surface area (BSA) affected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Prealbumin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cognitions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in self management behaviors
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in pain and functioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hearing Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with virological cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of cases of endometritis after cesarean section
Endpoint domain: Adverse events/effects
Primary endpoint: ST-segment elevation/depression in the ECG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: haemodynamic variation of the transcutaneous oxygen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Fasting Plasma Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of Target Vessel Revascularization (TVR) at 9 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of PMS symptoms severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of PMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants who Died From Any Cause
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants with Myocardial Infarction or Recurrent Ischemic Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Abdominal pain severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Optic Nerve Sheath Diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in regional cerebral oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Plasma concentrations of unchanged form (ng/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary excretions of unchanged form (ng/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Serum erythropoietin (EPO) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Blepharitis Symptom measure (BLISS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma flavanol metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Numerical agreement between predicted post PCI QFR and post PCI dPR RFR-FFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Direct QFR post-PCI measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to Exhaustion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms of the disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of UTI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: numbers of patients with symptoms of the musculoskeletal system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Safety of CP-675,206
Endpoint domain: Adverse events/effects
Primary endpoint: orgasm score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Attack Frequencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Haemoglobin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Development of anti-AMG811 antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of asymptomatic SARS-CoV-2 infection
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of occurrence of particular symptoms of SARS-CoV-2 infection
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Suspicious Tumors Detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prevalence of lesion detection (sensitivity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Mini-Mental State Examination (MMSE) score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean Revised Hasegawa's Dementia Scale (HDS-R) score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: change from baseline in Semmes-Weinstei monofilaments (SWM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: change from baseline in two-point discrimination (2PD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: change from baseline in grip power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Canadian Occupational Performance Measure (COPM)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Revascularisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half emptying time (T50)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in Nocturnal Enuresis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alpha angles as a measure of dysplasia of the infant hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Maximum Perioperative Blood Glucose Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to maximum plasma concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: side reactions at MSA injection site of the skin
Endpoint domain: Adverse events/effects
Primary endpoint: unstable changes of vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: development of abnormal biochemical parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of biofilm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of eradication of biofilm production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Threat Bias Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Social Phobia and Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Peak eosinophil count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cardiac autonomic neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants With a Response
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Treatment-related Adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnostic accuracy of POCUS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reconstruction flap failure
Endpoint domain: Adverse events/effects
Primary endpoint: UV exposure behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delayed recall as assessed by the Hopkins Verbal Learning Test-Revised
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Breast Cancer Lesions Characterized as Malignant or Benign
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Migration efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Structured Clinical Interview for DSM-IV (SCID)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the effect curve for newly generated beta-Amyloid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change From Baseline in Maintenance of Wakefullness Test (MWT) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Clinical Global Impression of Change (CGI-C) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Off-ventilator Spontaneous Breathing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Common Deletion (CD) Value in DNA of Skin Biopsy Sample
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 8-oxo-7,8-dihydro-2'-Deoxyguanosine (8-oxo-dG) Quantification in Skin Biopsy Sample
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Penetration Aspiration Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Sweat Chloride Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of right ventricular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quantitative CTPA score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in uterine fibroid symptom severity scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of Needle Tip Identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Unacceptable Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Requiring Low-dose Bevacizumab or Steroid
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of patients with virus reactivation
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnostic accuracy of serum bilirubin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vascular invasion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: regional lymph node metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Efficacy rate on gastroscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sexuality problems
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Intimacy problems
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Study adherence
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Efficacy of Combination Immunotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Complete Response Rate by Lugano Classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Unacceptable Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Standing Balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pediatric neoplastic response to chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sensitivity to oxaliplatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Temporomandibular dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Midnight cortisol levels < 5.0 mcg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Standard two day dexamethasone suppression test < 1.8 mcg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Smartphones addiction scale (SAS)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Overall survival after two years of treatment
Endpoint domain: Mortality/survival
Primary endpoint: Maximum tolerated dose (MTD) of linsitinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of major and CRNM bleeding events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Flicker induced blood flow alterations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Ischemic or hemorrhagic stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Lung function recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in cigarettes per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: superficial wound infection of stoma site
Endpoint domain: Adverse events/effects
Primary endpoint: day-3 parasite positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of radioactive dose recovered
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical outcome of the abdominal scar
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to healing of the abdominal wound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction of abdominal scar appearance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Hemoglobin Concentration From Baseline to 90 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Hematocrit in Concentration From Baseline to 90 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes